LXRX LEXICON PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, LEXICON PHARMACEUTICALS INC reported revenue of $692K (down 97.6% from a year earlier), net income of −$31.8M and diluted EPS of −$0.07; over the last four quarters revenue was $41.5M and net income −$61.1M; for the fiscal year ended December 2025 revenue was $49.8M, up 60.2% on the year before.
LXRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $49.8M, gross profit n/a, operating income −$48.9M, net income −$50.3M (margin -101.1%), EPS −$0.14
- Fiscal year ended Dec 2024: revenue $31.1M, gross profit n/a, operating income −$197M, net income −$200M (margin -644.8%), EPS −$0.63
- Fiscal year ended Dec 2023: revenue $1.20M, gross profit n/a, operating income −$172M, net income −$177M (margin -14710.9%), EPS −$0.80
- Fiscal year ended Dec 2022: revenue $139K, gross profit n/a, operating income −$101M, net income −$102M (margin -73341.0%), EPS −$0.62
- Fiscal year ended Dec 2021: revenue $298K, gross profit n/a, operating income −$87.1M, net income −$87.8M (margin -29449.0%), EPS −$0.60
LXRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $692K (down 97.6% year over year), net income −$31.8M, EPS −$0.07
- Quarter ended Mar 31, 2026: revenue $21.1M (up 1572.1% year over year), net income −$1.04M, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue $5.49M (down 79.3% year over year), net income −$15.5M, EPS −$0.04
- Quarter ended Sep 30, 2025: revenue $14.2M (up 710.4% year over year), net income −$12.8M, EPS −$0.04
- Quarter ended Jun 30, 2025: revenue $28.9M (up 1652.6% year over year), net income $3.25M, EPS $0.01
- Quarter ended Mar 31, 2025: revenue $1.26M (up 11.7% year over year), net income −$25.3M, EPS −$0.07
- Quarter ended Dec 31, 2024 (from the annual report): revenue $26.6M (up 3688.0% year over year), net income −$33.8M, EPS −$0.08
- Quarter ended Sep 30, 2024: revenue $1.75M (up 980.2% year over year), net income −$64.8M, EPS −$0.18
- Quarter ended Jun 30, 2024: revenue $1.65M (up 419.6% year over year), net income −$53.4M, EPS −$0.17
- Quarter ended Mar 31, 2024: revenue $1.13M (up 4608.3% year over year), net income −$48.4M, EPS −$0.20
- Quarter ended Dec 31, 2023 (from the annual report): revenue $701K, net income −$49.8M, EPS −$0.20
- Quarter ended Sep 30, 2023: revenue $162K (up 315.4% year over year), net income −$50.5M, EPS −$0.21
- Quarter ended Jun 30, 2023: revenue $317K (up 805.7% year over year), net income −$44.9M, EPS −$0.22
- Quarter ended Mar 31, 2023: revenue $24.0K, net income −$31.9M, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$30.5M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $39.0K (up 69.6% year over year), net income −$23.4M, EPS −$0.13
- Quarter ended Jun 30, 2022: revenue $35.0K (down 85.0% year over year), net income −$24.6M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.5M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $14.0K, net income −$25.6M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $23.0K, net income −$23.1M, EPS −$0.16
LXRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$67.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$179M, share buybacks $1.73M
- Fiscal year ended Dec 2023: operating cash flow −$162M, share buybacks $824K
- Fiscal year ended Dec 2022: operating cash flow −$88.9M, share buybacks $864K
- Fiscal year ended Dec 2021: operating cash flow −$87.0M, share buybacks $2.68M
LXRX balance sheet
- Jun 30, 2026: cash $40.9M, total assets $250M, total liabilities $75.5M, shareholders' equity $175M, long-term debt $51.4M
- Mar 31, 2026: cash $38.1M, total assets $269M, total liabilities $66.0M, shareholders' equity $203M, long-term debt $49.7M
- Dec 31, 2025: cash $34.3M, total assets $185M, total liabilities $77.4M, shareholders' equity $108M, long-term debt $49.4M
- Sep 30, 2025: cash $49.7M, total assets $206M, total liabilities $85.8M, shareholders' equity $120M, long-term debt $56.5M
- Jun 30, 2025: cash $21.4M, total assets $226M, total liabilities $96.1M, shareholders' equity $129M, long-term debt $56.1M
- Mar 31, 2025: cash $62.9M, total assets $298M, total liabilities $175M, shareholders' equity $123M, long-term debt $58.6M
- Dec 31, 2024: cash $66.7M, total assets $298M, total liabilities $152M, shareholders' equity $146M, long-term debt $100M
- Sep 30, 2024: cash $34.6M, total assets $321M, total liabilities $143M, shareholders' equity $179M, long-term debt $99.9M
What is LXRX's revenue?
LEXICON PHARMACEUTICALS INC reported $41.5M of revenue over its last four quarters, through June 30, 2026.
Is LXRX profitable?
No. LEXICON PHARMACEUTICALS INC lost $61.1M over the last four quarters.
What is LXRX's EPS?
Diluted earnings per share over the last four quarters were −$0.15; −$0.07 in the latest quarter.